Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion

References

• Furst DE. Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum. 2009;39(1):18–29.
   PubMed Web of Science ®Google Scholar
• Duraisingham SS, Buckland MS, Grigoriadou S, et al. Secondary antibody deficiency. Expert Rev Clin Immunol. 2014;10(5):583–591.
   PubMed Web of Science ®Google Scholar
• Compagno N, Malipiero G, Cinetto F, et al. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. J Allergy Clin Immunol Pract. 2014;2(5):594–600.
   PubMed Web of Science ®Google Scholar
• Arai Y, Yamashita K, Mizugishi K, et al. Risk factors for hypogammaglobulinemia after allo-SCT. Bone Marrow Transplant. 2014;49(6):859–861.
   PubMed Web of Science ®Google Scholar
• Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol. 2009;146(1):120–122.
   PubMed Web of Science ®Google Scholar
• De La Torre I, Leandro MJ, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology (Oxford). 2012;51(5):833–840.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Kalil AC, Qiu F, et al. What is the impact of hypogammaglobulinemia on the rate of infections and survival in solid organ transplantation? A meta-analysis. Am J Transplant. 2013;13(10):2601–2610.
   PubMed Web of Science ®Google Scholar
• Kano G, Nakatani T, Yagi K, et al. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia. Immunol Lett. 2014;159(1–2):76–78.
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60 e4.
   PubMed Web of Science ®Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137(1):21–30.
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Guerra A, et al. Effectiveness of immunoglobulin replacement therapy on clinical outcome in patients with primary antibody deficiencies: results from a multicenter prospective cohort study. J Clin Immunol. 2011;31(3):315–322.
   PubMed Web of Science ®Google Scholar
• Simon H, Späth P. IVIG–mechanisms of action. Allergy. 2003;58(7):543–552.
   PubMed Web of Science ®Google Scholar
• Elluru SR, Kaveri SV, Bayry J. The protective role of immunoglobulins in fungal infections and inflammation. Semin Immunopathol. 2015;37(2):187–197.
   PubMed Web of Science ®Google Scholar
• Orange JS, Du W, Falsey AR. therapeutic immunoglobulin selected for high antibody titer to RSV also contains high antibody titers to other respiratory viruses. Front Immunol. 2015;6:431.
   PubMed Web of Science ®Google Scholar
• Bayry J, Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun. 2011;36(1):9–15.
   PubMed Web of Science ®Google Scholar
• Mitrevski M, Marrapodi R, Camponeschi A, et al. Intravenous Immunoglobulin and Immunomodulation of B-Cell - in vitro and in vivo Effects. Front Immunol. 2015;6:4.
   PubMed Web of Science ®Google Scholar
• Paquin-Proulx D, Sandberg JK. Persistent immune activation in CVID and the role of IVIg in its suppression. Front Immunol. 2014;5:637.
   PubMed Web of Science ®Google Scholar
• Cavaliere FM, Prezzo A, Conti V, et al. Intravenous immunoglobulin replacement induces an in vivo reduction of inflammatory monocytes and retains the monocyte ability to respond to bacterial stimulation in patients with common variable immunodeficiencies. Int Immunopharmacol. 2015;28(1):596–603.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma. 2009;50(5):764–772.
   PubMed Web of Science ®Google Scholar
• Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106–111.
   PubMed Web of Science ®Google Scholar
• Compagno N, Cinetto F, Semenzato G, et al. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–1106.
   PubMed Web of Science ®Google Scholar
• Günther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol. 2013;57(7):527–535.
   PubMed Web of Science ®Google Scholar
• Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;4:Cd006501.
   PubMed Web of Science ®Google Scholar
• Imbach P. Immunotherapy with intravenous immunoglobulins. London: Academic Press; 1991.
   Google Scholar
• Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2Suppl 1):S9–56.
   PubMed Web of Science ®Google Scholar
• Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541–564.
   PubMed Web of Science ®Google Scholar
• Australia NBA. Criteria for the clinical use of intravenous immunoglobulin in Australia. 2nd ed. Canberra: National Blood Authority, Commonwealth of Australia; 2012. Available from http://www.blood.gov.au/pubs/ivig/conditions-for-which-IVIg-has-an-established-therapeutic-role.html - cdn-01
   Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520.
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clinic of Barcelona experience. Blood. 2009;114(10):2044–2050.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281–283.
   PubMed Web of Science ®Google Scholar
• Visentin A, Compagno N, Cinetto F, et al. Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy. Haematologica. 2015;100(12):e515–8.
   PubMed Web of Science ®Google Scholar
• Svensson T, Höglund M, Cherif H. Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. Scand J Infect Dis. 2013;45(7):537–542.
   PubMed Web of Science ®Google Scholar
• Freeman JA, Crassini KR, Best OG, et al. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54(1):99–104.
   PubMed Web of Science ®Google Scholar
• Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573–581.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044–6055.
   PubMed Web of Science ®Google Scholar
• Cherif H, Landgren O, Konradsen HB, et al. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine. 2006;24(1):75–81.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 2005;130(1):96–98.
   PubMed Web of Science ®Google Scholar
• Svensson M, Dahlin U, Kimby E. Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients. Br J Haematol. 2012;156(3):407–409.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Cullen M, Steven N, Billingham L, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England J Med. 2005;353(10):988–998.
   PubMed Web of Science ®Google Scholar
• Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet (London, England). 1994;343(8905):1059–1063.
   PubMed Web of Science ®Google Scholar
• Holmström MO, Gimsing P, Abildgaard N, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90(4):E73–E4.
   PubMed Web of Science ®Google Scholar
• De Angelis F, Tosti ME, Capria S, et al. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: a retrospective cohort study. Leuk Res. 2015;39(12):1382–1388.
   PubMed Web of Science ®Google Scholar
• Jayne D. Rituximab treatment for vasculitis. Clin J Am Soc Nephrol. 2010;5(8):1359–1362.
   PubMed Web of Science ®Google Scholar
• Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev. 2013;27(3):171–178.
   PubMed Web of Science ®Google Scholar
• Ammann EM, Jones MP, Link BK, et al. Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. Blood. 2016;127(2):200–207.
   PubMed Web of Science ®Google Scholar
• Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev. 2007;6(4):257–259.
   PubMed Web of Science ®Google Scholar
• Björkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90(4):286–293.
   PubMed Web of Science ®Google Scholar
• Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388–395.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Borte M, Ochs HD, et al. Vivaglobin Clinical Study G. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126(1):81–88.
   PubMed Web of Science ®Google Scholar
• Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy. 2014;6(5):553–567.
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012;130(4):951–7e11.
   PubMed Web of Science ®Google Scholar
• EMA. Kiovig 100 mg/mL, summary of product characteristics [PDF] [Internet]. European Medicines Agency; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000628/WC500043416.pdf
   Google Scholar
• EMA. HyQvia, Summary of Product Characteristics [PDF]. European Medicines Agency; 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002491/WC500143851.pdf
   Google Scholar
• EMA. Hizentra: EPAR - Product Information; 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002127/WC500107057.pdf
   Google Scholar
• Kerr J, Quinti I, Eibl M, et al. Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in Europe. Front Immunol. 2014;5:629.
   PubMed Web of Science ®Google Scholar
• Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol. 1992;89(3):374–377.
   PubMed Web of Science ®Google Scholar
• Gamm H, Huber C, Chapel H, et al. Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol. 1994;97(Suppl 1):17.
   PubMed Web of Science ®Google Scholar